Mar 06, 2018
Glenmark Pharmaceutical S.A. to Invest in New Translational Research Group at Biopole Lausanne-Epalinges
Mar 05, 2018
Glenmark Pharmaceuticals Presents New Data on Ryaltris(TM), an Investigational Product for the Treatment of Seasonal Allergic Rhinitis at the AAAAI/WAO Joint Congress
Feb 21, 2018
Glenmark Pharmaceuticals Enters Exclusive Collaboration Agreement with SCD Pharmaceuticals, South Korea for Ophthalmic Solution Products
Feb 16, 2018
Glenmark Pharmaceuticals Presents New Data on GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting
Jan 24, 2018
Glenmark Pharmaceuticals Presents Preliminary Biomarker Data on GBR 1302, a HER2xCD3 Bispecific Monoclonal Antibody, at the ASCO-SITC Clinical Immuno-Oncology Symposium
Dec 13, 2017
Glenmark Pharmaceuticals Announces Top-Line Results from a Phase 3 Safety Study Evaluating Ryaltris(TM) in Patients with Perennial Allergic Rhinitis
Dec 07, 2017
Glenmark Pharmaceuticals Announces Dosing of First Patient With Investigational Immuno-Oncology Agent GBR 1342
Dec 07, 2017
Glenmark Pharmaceuticals Announces Dosing of First Patient With Investigational Immuno-Oncology Agent GBR 1342
Oct 23, 2017
Glenmark Pharmaceuticals Presenting New Data from Respiratory Portfolio at the ACAAI Annual Scientific Meeting 2017
Jul 31, 2017
Glenmark Pharmaceuticals Reports Positive Data in a Phase 2a Study of GBR 830 for the Treatment of Patients with Atopic Dermatitis
Jul 18, 2017
Glenmark Pharmaceuticals Enters Exclusive Agreement with Cyndea Pharma S.L. for Generic Soft-Gelatin Capsule Drug Products
Jun 20, 2017
Glenmark Pharmaceuticals Licenses Small Molecule Oncology Compound from APC Therapeutics to Expand Immuno-Oncology Portfolio